Press releases

23rd November 2022

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

STC-15 is the first molecule specifically targeting an RNA methyltransferase to enter clinical development

20th October 2022

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3. STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022.

12th September 2022

Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets

7th September 2022

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

Industry veteran to lead STORM as it transitions into a clinical-stage company with a pipeline of products targeting RNA modifying enzymes

3rd May 2022

STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme

STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK to research and develop new drugs directed against a unique SARS-CoV2 protein utilizing STORM’s proprietary RNA epigenetic platform.